What triggered Novo Nordisk shares' latest price surge

Traders Union
All News
Financial News
Novo Nordisk rises 2.32% to $46.71

Highlights

Novo Nordisk's Q1 2026 results surpassed expectations with 32% sales growth driven by robust US oral Wegovy prescriptions.
Profitability benefited from a provision reversal tied to the US 340B Drug Pricing Program and a new AI-focused partnership with OpenAI.
Technical analysis indicates short-term overbought conditions with resistance near $46.95 and a likely sideways or downside move in the coming sessions.

Profit jump and AI partnership as sales outpace expectations

Novo Nordisk reported strong first-quarter 2026 financial results, driven by higher-than-expected sales of its new oral Wegovy weight-loss pill in the United States. The adjusted operating profit reached DKK 32,858 million for the period, with sales up 32% at constant exchange rates, partly due to a provision reversal linked to the US 340B Drug Pricing Program. The company also formed a partnership with OpenAI to utilize artificial intelligence in drug discovery and manufacturing operations.

Anton Kharitonov, expert at Traders Union, notes Novo Nordisk’s inability to clear the long-term 200-day moving average despite short-term momentum. He highlights mixed signals from technical indicators and points to overbought conditions that raise red flags for near-term buyers. The recent upside is driven partly by strong Wegovy pill sales and artificial intelligence news, yet these factors have not translated into a convincing trend shift. Kharitonov believes the lack of weekly buy signals, combined with heightened intraday volatility, makes any bullish outlook questionable. "Traders should be wary of chasing this move as consolidation and downside risk appear more likely than further gains."

Viktoras Karapetjanc, expert at Traders Union, highlights Novo Nordisk’s robust quarterly performance as a catalyst for further growth. He sees the rising sales of the oral Wegovy pill and the strategic OpenAI partnership as powerful drivers of optimism. Karapetjanc maintains that the bullish structure remains intact above $46.50, with technical and fundamental factors aligning for continued upside. Forward-looking, he expects new setups to emerge if upside resistance is cleared. "This market offers attractive entry opportunities for bulls, and I see potential for further advances once consolidation is resolved."

Overbought signals persist as upward momentum faces weak trend strength

Momentum signals are mixed. Moving Average Convergence Divergence (MACD) signals upward momentum on the daily chart, while the Average Directional Index (ADX) shows weak trend strength. Both the Relative Strength Index (RSI) and Commodity Channel Index (CCI) indicate overbought conditions, confirmed by Stochastic RSI being fully saturated. Bull/Bear Power (BBP) also highlights clear buyer dominance intraday and flags overbought conditions. The Awesome Oscillator supports the prevailing upward move. The stock is up $1.06 or 2.32% on the day, opening with an upside gap of about $0.65 and trading near the high of its daily range. Intraday volatility stands at 1.91%. The price action shows sustained strength toward session highs following an initial bullish surge.

Earlier, analysts noted that Novo Nordisk’s robust earnings performance was tempered by persistent overbought signals and growing competitive pressures, raising the risk of a short-term pullback. The current analysis reinforces this cautious outlook by highlighting ongoing overbought technicals and weak trend strength, suggesting that traders should closely monitor $46.50 as a critical support level in the days ahead.

Source of Data: NVO Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.